Weiwei Wang

Dr. Weiwei Wang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
WWWeiwei Wang
Weiwei Wang
ZHZhijie Huang
Zhijie Huang
YSYinxiangzi Sheng
Yinxiangzi Sheng
JZJingfang Zhao
Jingfang Zhao
KSKambiz Shahnazi
Kambiz Shahnazi
GJGuoliang Jiang
Guoliang Jiang

7 October 2021 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
JSJiayao Sun
Jiayao Sun
ZWZheng Wang
Zheng Wang
YSYinxiangzi Sheng
Yinxiangzi Sheng
XMXue Ming
Xue Ming
GJGuo-Liang Jiang
Guo-Liang Jiang
WWWeiwei Wang
Weiwei Wang

17 December 2022 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
WWWeiwei Wang
Weiwei Wang
PLPing Li
Ping Li
KSKambiz Shahnazi
Kambiz Shahnazi
XWXiaodong Wu
Xiaodong Wu
JZJingfang Zhao
Jingfang Zhao
Background: Compelling evidence shows the association between the relative biological effectiveness (RBE) of carbon‐ion radiotherapy (CIRT) and the dose averaged linear energy transfer (LETd). However, the ability to calculate the LETd in commercially available treatment planning systems (TPS) is lacking.Purpose: This study aims to develop a method of calculating the LETd of CIRT plans that could be robustly carried out in RayStation (V10B, Raysearch, Sweden).Methods: The calculation used the fragment spectra in RayStation for the CIRT treatment planning. The dose‐weighted averaging procedure was supported by the microdosimetric kinetic model (MKM). The MKM‐based pencil beam dose engine (PBA, v4.2) for calculating RBE‐weighted doses was reformulated to become a LET‐weighted calculating engine. A separate module was then configured to inversely calculate the LETd from the absorbed dose of a plan and the associated fragment spectra. In this study, the ion and energy‐specific LET table in the LETd module was further matched with the values decoded from the baseline data of the Syngo TPS (V13C, Siemens, Germany). The LETd distributions of several monoenergetic and modulated beams were calculated and validated against the values derived from the Syngo TPS and the published data.Results: The differences in LETds of the monoenergetic beams between the new method and the traditional method were within 3% in the entrance and Bragg‐peak regions. However, a larger difference was observed in the distal region. The results of the modulated beams were in good agreement with the works from the published literature.Conclusions: The method presented herein reformulates the MKM dose engine in the RayStation TPS to inversely calculate LETds. The robustness and accuracy were demonstrated.

17 May 2023 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
WWWeiwei Wang
Weiwei Wang
WSWei Sun
Wei Sun
HSHao Shen
Hao Shen
JZJingfang Zhao
Jingfang Zhao
Background: The study objective was to validate the relative biological effectiveness (RBE) calculated by the modified microdosimetric kinetic model in RayStation (Ray-MKM) for active-energy scanning carbon-ion radiotherapy. Methods: The Ray-MKM was benchmarked using a spread-out Bragg-peak (SOBP) plan, which was suggested in literature from the National Institute of Radiobiological Science (NIRS) in Japan. The residual RBE differences from the MKM at NIRS (NIRS-MKM) were derived using several SOBP plans with different ranges, SOBP widths, and prescriptions. To investigate the origins of the differences, we compared the saturation-corrected dose-mean specific energy $$Z_{1D}^{*}$$ Z 1 D ∗ of the aforementioned SOBPs. Furthermore, we converted the RBE-weighted doses with the Ray-MKM to those with local effect model I (LEM doses). The purpose was to investigate whether the Ray-MKM could reproduce the RBE-weighted conversion study. Results: The benchmark determined the value of the clinical dose scaling factor, $$F_{clin}$$ F clin , as 2.40. The target mean RBE deviations between the Ray-MKM and NIRS-MKM were median: 0.6 (minimum: 0.0 to maximum: 1.69) %. The $$Z_{1D}^{*}$$ Z 1 D ∗ difference in-depth led to the RBE difference in-depth and was remarkable at the distal end. The converted LEM doses from the Ray-MKM doses were comparable (the deviation being − 1.8–0.7%) to existing literature. Conclusion: This study validated the Ray-MKM based on our active-energy scanning carbon-ion beam via phantom studies. The Ray-MKM could generate similar RBEs as the NIRS-MKM after benchmarking. Analysis based on $$Z_{1D}^{*}$$ Z 1 D ∗ indicated that the different beam qualities and fragment spectra caused the RBE differences. Since the absolute dose differences at the distal end were small, we neglected them. Furthermore, each centre may determine its centre-specific $$F_{clin}$$ F clin based on this approach.

13 April 2021 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
WWWeiwei Wang
Weiwei Wang
PLPing Li
Ping Li
YSYinxiangzi Sheng
Yinxiangzi Sheng
ZHZhijie Huang
Zhijie Huang
JZJingfang Zhao
Jingfang Zhao
QZQing Zhang
Qing Zhang
Background: The study objective was to establish the local effect model (LEM) rectum constraints for 12-, 8-, and 4-fraction carbon-ion radiotherapy (CIRT) in patients with localized prostate carcinoma (PCA) using microdosimetric kinetic model (MKM)-defined and LEM-defined constraints for 16-fraction CIRT. Methods: We analyzed 40 patients with PCA who received 16- or 12-fraction CIRT at our center. Linear-quadratic (LQ) and RBE-conversion models were employed to convert the constraints into various fractionations and biophysical models. Based on them, the MKM LQ strategy converted MKM rectum constraints for 16-fraction CIRT to 12-, 8-, and 4-fraction CIRT using the LQ model. Then, MKM constraints were converted to LEM using the RBE-conversion model. Meanwhile the LEM LQ strategy converted MKM rectum constraints for 16-fraction CIRT to LEM using the RBE-conversion model. Then, LEM constraints were converted from 16-fraction constraints to the rectum constraints for 12-, 8-, and 4-fraction CIRT using the LQ model. The LEM constraints for 16- and 12-fraction CIRT were evaluated using rectum doses and clinical follow-up. To adapt them for the MKM LQ strategy, CNAO LEM constraints were first converted to MKM constraints using the RBE-conversion model. Results: The NIRS (i.e. DMKM|v, V-20%, 10%, 5%, and 0%) and CNAO rectum constraints (i.e. DLEM|v, V-10 cc, 5 cc, and 1 cc) were converted for 12-fraction CIRT using the MKM LQ strategy to LEM 37.60, 49.74, 55.27, and 58.01 Gy (RBE), and 45.97, 51.70, and 55.97 Gy (RBE), and using the LEM LQ strategy to 39.55, 53.08, 58.91, and 61.73 Gy (RBE), and 49.14, 55.30, and 59.69 Gy (RBE). We also established LEM constraints for 8- and 4-fraction CIRT. The 10-patient RBE-conversion model was comparable to 30-patient model. Eight patients who received 16-fraction CIRT exceeded the corresponding rectum constraints; the others were within the constraints. After a median follow-up of 10.8 months (7.1–20.8), No ≥ G1 late rectum toxicities were observed. Conclusions: The LEM rectum constraints from the MKM LQ strategy were more conservative and might serve as the reference for hypofractionated CIRT. However, Long-term follow-up plus additional patients is necessary.

2 January 2024 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
XMXue Ming
Xue Ming
JMJingfang Mao
Jingfang Mao
NMNingyi Ma
Ningyi Ma
JCJian Chen
Jian Chen
WWWeiwei Wang
Weiwei Wang
KWKailiang Wu
Kailiang Wu
Objective. To assess the dosimetric consequences and the normal tissue complication probability (NTCP) for the organs at risk (OARs) in intensity-modulated particle radiotherapy of proton (IMPT) and carbon-ion (IMCT) using a fixed-beam delivery system when compared with intensity-modulated photon radiotherapy (IMRT) for locally advanced small-cell lung cancer. Approach. The plans were all designed under the same total relative biological effectiveness (RBE)-weighted prescription dose, in which the planning target volume (PTV) of the internal gross target volume(IGTV) and the PTV of the clinical target volume was irradiated with 69.3 Gy (RBE) and 63 Gy (RBE), respectively, using a simultaneously integrated boosting (SIB) technique. NTCPs were estimated for heart, lung, esophagus and spinal cord by Lyman–Kutcher–Burman (LKB) and logistic models. Dose escalation was simulated under the desired NTCP values (0.05, 0.10 and 0.50) of the three radiation techniques. Main results. Under the similar target coverage, almost all OARs were significantly better spared (p < 0.05) when using the particle radiotherapy except for D1cc (the dose to 1 cm3 of the volume) of the proximal bronchial tree (p > 0.05). At least 57.6% of mean heart dose, 28.8% of mean lung dose and 19.1% of mean esophageal dose were reduced compared with IMRT. The mean NTCP of radiation-induced pneumonitis (RP) in the ipsilateral lung was 0.39 ± 0.33 (0.39 ± 0.31) in IMPT plans and 0.36 ± 0.32 (0.35 ± 0.30) in IMCT plans compared with 0.66 ± 0.30 (0.64 ± 0.28) in IMRT plans by LKB (logistic) models. The target dose could be escalated to 78.3/76.9 Gy (RBE) in IMPT/IMCT plans compared with 61.7 Gy (RBE) in IMRT plans when 0.50 of NTCP in terms of RP in the ipsilateral lung was applied. Significance. This study presents the potential of better control of the side effects and improvement of local control originating from the dosimetric advantage with the application of IMPT and IMCT with the SIB technique for locally advanced lung cancer, even with limited beam directions.